Indian anticoagulants market is estimated to grow at a CAGR of 8.8% during the forecast period. A significant rise in the demand for novel oral anticoagulants has been witnessed owing to its demonstrated safety and efficacy in trials and Indian government initiatives to reduce the prices of NOSCs. NOACs may be safer for patients as there is a low risk of bleeding, and these anticoagulants may also be highly effective for the prevention of blood clots compared to warfarin. NOACs are the ideal suggested drug class compared to warfarin, except for patients suffering from moderate to severe mitral stenosis or an artificial heart valve.
Get Free Sample Copy @ https://www.omrglobal.com/request-sample/indian-anticoagulants-market
NOACs comprises edoxaban, dabigatran, apixaban, and rivaroxaban. In July 2018, the Indian government has decreased the cost of one of the three drugs that are being prescribed in India by one-third. The Indian government has decreased the Dabigatran cost from nearly $1 per tablet to nearly $0.3. Over the 10 years, some evidence has suggested that NOACs could reduce the risk of stroke. Therefore, in 2018, the government has lowered the price of NOSCs in India, which is supporting to drive market growth.
Indian Anticoagulants Market-Segmentation
By Type
- Novel Oral Anticoagulants (NOACs)
- Vitamin K Antagonist
- Heparin and Low Molecular Weight Heparin (LMWH)
By Application
- Pulmonary Embolism
- Atrial Fibrillation/Myocardial Infarction (Heart Attack)
- Deep Vein Thrombosis (DVT)
- Others
